Residual symptoms in major depressive disorder after treatment with paroxetine and milnacipran

被引：0
|
作者：
Kesebir, S.
Simsek, Y.
机构：
来源：
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY | 2006年 / 9卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：S235 / S235
页数：1
相关论文
共 50 条
  • [1] Venlafaxine, Paroxetine and Milnacipran for Major Depressive Disorder: A Pragmatic 24-Week Study
    Chuang, Hui-Yu
    Chang, Yun-Hsuan
    Cheng, Ling-Yi
    Wang, Yu-Shan
    Chen, Shiou-Lan
    Chen, Shih-Heng
    Chu, Chun-Hsien
    Lee, I. Hui
    Chen, Po See
    Yeh, Tzung Lieh
    Yang, Yen Kuang
    Lu, Ru-Band
    CHINESE JOURNAL OF PHYSIOLOGY, 2014, 57 (05): : 265 - 270
  • [2] Residual symptoms and recurrence in major depressive disorder
    Spadone, C.
    Corruble, E.
    ENCEPHALE-REVUE DE PSYCHIATRIE CLINIQUE BIOLOGIQUE ET THERAPEUTIQUE, 2010, 36 : S108 - S111
  • [3] Vortioxetine in the treatment of major depressive disorder, addressing the core and residual symptoms
    Romero Guillena, S. L.
    Plasencia Garcia de Diego, B. O.
    Gotor Sanchez-Luengo, F.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2019, 29 : S35 - S36
  • [4] Comparison of escitalopram and paroxetine in the treatment of major depressive disorder
    Lin, Huang-Li
    Hsu, Ya-Ting
    Liu, Chia-Yih
    Chen, Chia-Hui
    Hsiao, Mei-Chun
    Liu, Yu-Li
    Shen, Winston W.
    Hsiao, Chin-Fu
    Liu, Shen-Ing
    Chang, Liang-Huey
    Tang, Hwa-Sheng
    Lai, Hsiang-Ling
    Lin, Pei-Sheng
    Lin, Keh-Ming
    Tsou, Hsiao-Hui
    INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 2013, 28 (06) : 339 - 345
  • [5] Triiodothyronine addition to paroxetine in the treatment of major depressive disorder
    Appelhof, BC
    Brouwer, JP
    van Dyck, R
    Fliers, E
    Hoogendijk, WJG
    Huyser, J
    Schene, AH
    Tijssen, JGP
    Wiersinga, WM
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2004, 89 (12): : 6271 - 6276
  • [6] A comparative study of milnacipran and imipramine in the treatment of major depressive disorder
    Lopez-Ibor, JJ
    Conesa, A
    CURRENT MEDICAL RESEARCH AND OPINION, 2004, 20 (06) : 855 - 860
  • [7] Bupropion in the treatment of major depressive disorder: a comparison with paroxetine
    Calandra, C.
    Terranova, F.
    Loiacono, P.
    Caudullo, V.
    Russo, R. G.
    Luca, M.
    Cafiso, M.
    JOURNAL OF PSYCHOPATHOLOGY, 2010, 16 (01): : 128 - 133
  • [8] RESIDUAL SYMPTOMS AFTER REMISSION OF MAJOR DEPRESSIVE DISORDER WITH FLUOXETINE AND RISK OF RELAPSE
    Iovieno, Nadia
    van Nieuwenhuizen, Adrienne
    Clain, Alisabet
    Baer, Lee
    Nierenberg, Andrew A.
    DEPRESSION AND ANXIETY, 2011, 28 (02) : 137 - 144
  • [9] The remission rate of milnacipran in the treatment of Japanese patients with major depressive disorder
    Sato, K
    Kamata, M
    Naito, S
    Higuchi, H
    Yoshida, K
    Takahashi, H
    Ito, K
    Narumi, A
    Sugawara, Y
    Shimizu, T
    INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2004, 7 : S179 - S180
  • [10] COGNITIVE-BEHAVIORAL TREATMENT OF RESIDUAL SYMPTOMS IN PRIMARY MAJOR DEPRESSIVE DISORDER
    FAVA, GA
    GRANDI, S
    ZIELEZNY, M
    CANESTRARI, R
    MORPHY, MA
    AMERICAN JOURNAL OF PSYCHIATRY, 1994, 151 (09): : 1295 - 1299
12345